The Role of Bactericidal/Permeability-Increasing Protein in Men with Chronic Obstructive Pulmonary Disease

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, updated. Bethesda, MD: National Heart, Lung and Blood Institute/World Health Organization, 2008 (http://www.goldcopd.org).
   Google Scholar
• Tan WC, Ng TP. COPD in Asia: Where East meets West. Chest 2008; 133:517–527.
   PubMed Web of Science ®Google Scholar
• Regional COPD Working Group. COPD prevalence in 12 Asia-Pacific countries and regions: Projections based on the COPD prevalence estimation model. Respirology 2003; 8:192–198.
   PubMed Web of Science ®Google Scholar
• Vogelzang PFJ, van der Gulden JW, Folgering H, Kolk JJ, Heederik D, Preller L, Tielen MJM, van Schayck CP (1998) Endotoxin exposure as a major determinant of lung function decline in pig farmers. Am J Respire Crit Care Med 1998; 157:15–18.
   PubMed Web of Science ®Google Scholar
• Thorne PS, Kulhankova K, Yin M, Cohn R, Arbes SJ, and Zeldin DC. Endotoxin exposure is a risk factor for asthma; the national survey of endotoxin in United States housing. Am J Respire Crit Care Med 2005; 172:1371–1377.
   PubMed Web of Science ®Google Scholar
• Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999; 115:829–835.
   PubMed Web of Science ®Google Scholar
• Russell RE, Culpitt SV, Dematos C, Donnely L, Smith M, Wiggins J, Barnes PJ. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloprotease-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respire Cell Mol Biol 2002; 26:602–609.
   PubMed Web of Science ®Google Scholar
• Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med 2000; 162(pt1):1355–1360.
   PubMedGoogle Scholar
• Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters FM. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 2002; 26:152–159.
   PubMed Web of Science ®Google Scholar
• Sajjan U, Ganesan S, Comstock AT, Shim J, Wang Q, Nagarkar DR, Zhao Y, Doldsmith AM, Sonestein J, Linn MJ, Curtis JL, Hershenson MB. Elastase- and LPS- exposed mice display altered responses to rhinovirus infection. Am J Physiol Lung Cell Mol Physiol 2009; 297:L931–L944.
   PubMed Web of Science ®Google Scholar
• Meng QR, Gideon KM, Harbo SJ, Renne RA, Lee MK. Gene expression profiling in lung tissue from mice exposed to cigarette smoke, lipopolysaccharide, or smoke plus lipopolysaccharide by inhalation. Inhal Toxicol 2006; 18:555–568.
   PubMed Web of Science ®Google Scholar
• Wittmann I, SchÖnefeld M, Aichele D, Groer G, Gessner A, Schnare M. Murine bactericidal/permeability-increasing protein inhibits the endotoxic activity of lipopolysaccharide and gram-negative bacteria. J Immunol 2008; 180:7546–7552.
   PubMed Web of Science ®Google Scholar
• Weiss J. Bactericidal/permeability-increasing protein (BPI): structure, function and regulation in host defense against Gram-negative bacteria. Biochem Soc Trans 2003; 31:785
   PubMed Web of Science ®Google Scholar
• Chien JW, Zhao LP, Hansen JA, Fan WH, Parimon T, Clark JG. Genetic variation in bactericidal/permeability- increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006; 107:2200–2207.
   PubMed Web of Science ®Google Scholar
• Levy O. A neutrophil-derived anti-infective molecule: Bactericidal/permeability-ßßincreasing protein. Antimicrob Agents Chemother 2000; 44:2925–2931.
   PubMed Web of Science ®Google Scholar
• Ruiz A.G, Casafont F, Teran A, De La Pena J, Estebanez A, Romero FP. Increased bactericidal/permeability increasing protein in patients with cirrhosis. Liver Int 2010; 30:94–101.
   PubMed Web of Science ®Google Scholar
• Groenewegen KH, Dentener MA, Wouters EFM. Longitudinal follow-up of systemic inflammation after acute exacerbatio of COPD. Respir Med 2007; 101:2409–2415.
   PubMed Web of Science ®Google Scholar
• Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, Rothe G, Schmitz G. Gene variants of the bactericidal/permeability-increasing protein and lipopolysaccharide binding protein in sepsis patients. Crit Care Med 2001; 29:557–566.
   PubMed Web of Science ®Google Scholar
• Hubacek JA, Aslanidis C, Buchler C, Schmitz G. PstI-polymorphismin the human bactericidal permeability increasing protein (BPI) gene. Clin Genet: 1979; 52:249.
   Google Scholar
• Maris NA, de Vos A.F, Dessing MC, Spek CA, Lutter R, Jansen HM, van der Zee JS, Bresser P, van der Poll T. (2005) Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005; 172:878–884.
   PubMed Web of Science ®Google Scholar
• Krawczak M, Reiss J, Cooper DN. The mutational spectum of single base-pair substitutions in mENA splice junctions of human genes: causes and consequences. Hum Genet 1992; 90:41–54.
   PubMed Web of Science ®Google Scholar
• Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: Exonic mutations that affect splicing. Natrue Rev Genet 2002; 3:285–298.
   PubMed Web of Science ®Google Scholar
• Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen J, Schmeiegel W, Griga T. A polymorphism of the bacterial/permeability protein gene is associated with Crohn's disease. J Clin Gastroenterol 2005; 39:282–283.
   PubMed Web of Science ®Google Scholar
• Yang P, Tremanine WJ, Meyer RL, Prakash UB. Alpha 1-antitrypsin deficiency and inflammatory bowel diseases. Mayo Clin Proc 2000; 75: 450–455.
   PubMed Web of Science ®Google Scholar
• Ekbom A, Brandt L, Granath F, Lofdahl C-G, Egesten A. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. Lung 2008; 186: 167–172.
   PubMed Web of Science ®Google Scholar
• Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of overspill of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010; 65:930–936.
   PubMed Web of Science ®Google Scholar
• Eagan TML, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Damas JK, Aukrust P, Bakke PS. Systemic inflammatory markers in COPD: results from the Bergen COPD cohort study. Eur Respir J 2010; 35:540–548.
   PubMed Web of Science ®Google Scholar
• Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF, Lipinska I, O'Connor GT, Benjamin EJ. Systemic inflammation and COPD. The Framingham heart study. Chest 2008; 133: 19–25.
   PubMed Web of Science ®Google Scholar
• Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ, Giroir BP. Recombinant bactericial/permeability- increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomized trial. Lancet 2000; 356:961–967.
   PubMed Web of Science ®Google Scholar